Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01564862 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder
A Phase 2 study of Depressive Disorder, Major, sponsored by Takeda.
- Completed
- Registry status
- Phase 2
- Development phase
- 602
- Enrollment target
- 20
- Study locations
NCT01564862 is a Phase 2 study of Depressive Disorder, Major that has completed, run by Takeda. The registered enrollment target is 602 participants, above the 231-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (161% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT01564862, a Phase 2 study of Depressive Disorder, Major, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 602 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the effects of Lu AA21004, once daily (QD), on cognitive dysfunction in patients with major depressive disorder.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Duloxetine
- DRUG vortioxetine (Lu AA21004)
Study Locations (20)
California
- - Bellflower
- - Carson
- - Cerritos
- - Glendale
- - Imperial
- - Los Angeles
- - Norwalk
- - Oakland
- - Paramount
- - San Bernardino
- - Santa Ana
- - Wildomar
Florida
- - Lauderhill
- - Miami
- - Orlando
Colorado
- - Colorado Springs
- - Denver
Arizona
- - Tucson
Arkansas
- - Little Rock
Connecticut
- - Norwalk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 602 participants |
| Start Date | 2012-04 |
| Est. Completion | 2014-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01564862
The ClinicalTrials.gov registry entry for NCT01564862 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 602 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 231-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (161% higher). The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Depressive Disorder, Major appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT01564862 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT01564862 about?
NCT01564862 is a clinical study titled "Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder". The purpose of this study is to evaluate the effects of Lu AA21004, once daily (QD), on cognitive dysfunction in patients with major depressive disorder.
What is the current status of trial NCT01564862?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 602 participants. The study started on 2012-04. Estimated completion is 2014-02.
What conditions does trial NCT01564862 study?
This clinical trial studies the following conditions: Depressive Disorder, Major.
What interventions are being tested in trial NCT01564862?
The interventions under investigation include: Placebo (DRUG), Duloxetine (DRUG), vortioxetine (Lu AA21004) (DRUG).
Who is sponsoring clinical trial NCT01564862?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01564862 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depressive Disorder, Major
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab
RECRUITING · Phase 2
-
Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation
RECRUITING · Phase 2
-
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
RECRUITING · Phase 2
-
A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder
RECRUITING · Phase 2
-
Individualized Functional Connectivity Targeting in aiTBS for Depression
ACTIVE NOT RECRUITING · Phase 2
-
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.